ReviewOncoTargets and therapy2026
Traditional Chinese Medicine in Cushing's Syndrome: A Narrative Review of Pathophysiology and Potential Therapeutic Effects.
Review in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article employs a narrative review approach to systematically elucidate the pathophysiological mechanisms of Cushing Syndrome (CS), with a particular focus on exploring the theoretical foundations, clinical applications, and future directions of Traditional Chinese Medicine (TCM) in its treatment. CS is an endocrine disorder caused by chronic excessive cortisol secretion, with dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis at its core. The article first outlines the epidemiological characteristics, pathophysiological mechanisms (including abnormalities in the cAMP/PKA signaling pathway and autocrine/paracrine dysregulation), and genetic basis (such as mutations in ARMC5, PRKACA, and other genes) of CS. Regarding diagnosis, it reviews the application of clinical symptom evaluation, biochemical tests (eg, dexamethasone suppression tests), and imaging techniques (eg, MRI, CT). The core of this review lies in its systematic evaluation of TCM's comprehensive strategies in treating CS. It provides a detailed analysis of the clinical application of TCM, including herbal formulations (eg, Buzhong Yiqi Decoction, Xiaoyao Powder variations), non-pharmacological therapies (eg, acupuncture, tuina), and integrated approaches, while summarizing potential evidence of their efficacy in alleviating symptoms, modulating immunity, and improving quality of life. Concurrently, it points out that the field currently lacks high-quality clinical research support, and that the mechanisms of action and standardized treatment protocols require further investigation. Finally, the article looks forward to the prospects of integrating TCM with modern medicine in treating CS, as well as future directions in basic research, clinical trials, and international collaboration. The aim is to provide a theoretical basis and practical reference for the treatment of CS with TCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.